levosimendan inn ˌliːvoʊsaɪˈmɛndən calcium sensitizer used management acutely decompensated congestive heart failure marketed trade name simdax orion corporation overall drug two fold mechanism action leads greater inotrophy increasing calcium sensitivity binds troponin results greater positive inotrophic force secondly drug able open atp sensitive potassium channels vascular smooth muscle cells vascular dilatory effects drug lead decreased preload afterload putting less work heart drug process review fda approved use united states yet levosimendan calcium sensitizer increases sensitivity heart calcium thus increasing cardiac contractility without rise intracellular calcium levosimendan exerts positive inotropic effect increasing calcium sensitivity myocytes binding cardiac troponin c calciumdependent manner also vasodilatory effect opening adenosine triphosphate atpsensitive potassium channels vascular smooth muscle cause smooth muscle relaxation combined inotropic vasodilatory actions result increased force contraction decreased preload decreased afterload moreover opening also mitochondrial atpsensitive potassium channels cardiomyocytes drug exerts cardioprotective levosimendan indicated inotropic support acutelydecompensated severe congestive heart failure situations conventional therapy sufficient cases inotropic support considered appropriate phase iii studies extensive clinical program including trials lido patients russlan revivei reviveii survive total clinical data base includes patients phase iib iii doubleblind randomized survive study despite reduction plasma btype natriuretic peptide level patients levosimendan group compared patients dobutamine group levosimendan significantly reduce allcause mortality however retrospective subgroup analysis levosimendan superior dobutamine treating patients history chf betablocker therapy hospitalized acute orion corporation originally developed levosimendan applied new drug application us however food drug administration fda requested trials conducted orion withdrew application november initially orion obtained approval market drug sweden since countries worldwide approved drug acute cardiac care remains unapproved north america currently phase iii development tenax therapeutics reduction morbidity patients pulmonary hypertension derived heart failure preserved ejection faction use levosimendan contraindicated patients moderatetosevere kidney impairment severe liver impairment severe ventricular filling outflow obstruction low blood pressure fast heart rate andor history abnormal heart rhythm torsades de common adverse drug reactions patients associated levosimendan therapy include headache hypotension arrhythmias atrial fibrillation extrasystoles atrial tachycardia ventricular tachycardia myocardial ischaemia hypokalaemia andor nausea rossi levosimendan marketed mgml concentrated solution iv infusion concentrate diluted glucose solution infusion httpsenwikipediaorgwikilevosimendan